Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease

[1]  H. Kirikoshi,et al.  Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. , 2012, Cell metabolism.

[2]  Jason M. Meyer,et al.  Scavenger Receptor CD36 Expression Contributes to Adipose Tissue Inflammation and Cell Death in Diet-Induced Obesity , 2012, PloS one.

[3]  Z. Kutalik,et al.  Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon‐alpha and ribavirin therapy , 2012, Hepatology.

[4]  R. Haba,et al.  Selenium deficiency is associated with insulin resistance in patients with hepatitis C virus-related chronic liver disease. , 2011, Nutrition research.

[5]  H. Rosen.  Clinical practice. Chronic hepatitis C infection. , 2011, The New England journal of medicine.

[6]  N. Mhaidat,et al.  The putative diabetic plasma marker, soluble CD36, is non‐cleaved, non‐soluble and entirely associated with microparticles , 2011, Journal of thrombosis and haemostasis : JTH.

[7]  O. Khalilzadeh,et al.  Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C. , 2011, Clinics and research in hepatology and gastroenterology.

[8]  J. González‐Gallego,et al.  Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C , 2011, Gut.

[9]  R. Silverstein,et al.  A CD36-dependent pathway enhances macrophage and adipose tissue inflammation and impairs insulin signalling , 2010, Cardiovascular research.

[10]  T. Masaki,et al.  Insulin resistance derived from zinc deficiency in non-diabetic patients with chronic hepatitis C. , 2010, Experimental and therapeutic medicine.

[11]  Sheng-Nan Lu,et al.  Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. , 2010, World journal of gastroenterology.

[12]  A. Handberg,et al.  Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. , 2010, The Journal of clinical endocrinology and metabolism.

[13]  S. Klein,et al.  Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications , 2010, Hepatology.

[14]  F. Ortega,et al.  Circulating soluble CD36 is a novel marker of liver injury in subjects with altered glucose tolerance. , 2009, The Journal of nutritional biochemistry.

[15]  F. Negro,et al.  Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[16]  Jie Zhou,et al.  Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. , 2008, Gastroenterology.

[17]  J. Dyck,et al.  Increased Hepatic CD36 Expression Contributes to Dyslipidemia Associated With Diet-Induced Obesity , 2007, Diabetes.

[18]  C. Pasquier,et al.  Detection and quantitation of HCV RNA using real‐time PCR after automated sample processing , 2007, Journal of medical virology.

[19]  Ralf Bartenschlager,et al.  Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81 , 2007, Hepatology.

[20]  N. Wong,et al.  Interferon α decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes , 2007, Gut.

[21]  Y. Kohgo,et al.  Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. , 2007, World journal of gastroenterology.

[22]  K. Højlund,et al.  Identification of the Oxidized Low-Density Lipoprotein Scavenger Receptor CD36 in Plasma: A Novel Marker of Insulin Resistance , 2006, Circulation.

[23]  K. Koike.  Hepatitis C as a metabolic disease: Implication for the pathogenesis of NASH. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[24]  D. Wendum,et al.  Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C , 2005, Gut.

[25]  Seppo Ylä-Herttuala,et al.  Analysis of gene and protein expression during monocyte-macrophage differentiation and cholesterol loading--cDNA and protein array study. , 2005, Atherosclerosis.

[26]  K. Koike,et al.  Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH , 2005, Journal of Gastroenterology.

[27]  R. Andrade,et al.  Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.

[28]  M. Manns,et al.  Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C , 2003, Hepatology.

[29]  M. Sampson,et al.  Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. , 2003, Atherosclerosis.

[30]  T. Nakata,et al.  Insulin sensitivity and lipid metabolism in human CD36 deficiency. , 2003, Diabetes care.

[31]  R. Cortese,et al.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.

[32]  R. Silverstein,et al.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. , 2001, The Journal of clinical investigation.

[33]  Timothy McCaffrey,et al.  A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation , 2001, Nature Medicine.

[34]  Kunihiko Kobayashi,et al.  Phenotype-genotype Correlation in CD36 Deficiency Types I and II , 2000, Thrombosis and Haemostasis.

[35]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[36]  Takao Tsuji,et al.  New Inuyama classification; new criteria for histological assessment of chronic hepatitis , 1996 .

[37]  E. Holmes,et al.  A proposed system for the nomenclature of hepatitis C viral genotypes , 1994, Hepatology.

[38]  G. Davis,et al.  Significance of serum hepatitis C virus RNA levels in chronic hepatitis C , 1993, The Lancet.

[39]  S. Kalra,et al.  Diabetology & Metabolic Syndrome , 2009 .

[40]  Myeong-Seok Lee,et al.  (Hepatitis C Virus Infection and Diabetes: Direct Involvement of the Virus in the Development of Insulin Resistance.) , 2004 .

[41]  宮岡 宏治.  CD36 deficiency associated with insulin resistance , 2002 .